On Wednesday, Canaccord Genuity adjusted its stock price target for Merit Medical Systems , Inc. (NASDAQ:MMSI), reducing it to $102 from $112, while continuing to recommend a Buy for the stock.
This change follows the company's first-quarter earnings report, which showed revenue of $323.5 million, a year-over-year increase of 8.7% and 7.0% on an organic constant currency (CC) basis. These figures surpassed the analyst's projection of $315.4 million and the consensus estimate of $315.5 million.
Merit Medical also exceeded expectations on adjusted earnings per share (EPS), reporting $0.77 against the anticipated $0.71. Despite this outperformance, the company chose not to revise its full-year guidance, opting to reaffirm the existing forecasts. This decision is believed to reflect the company's cautious approach to guidance early in the fiscal year.
The company's operating margin for the quarter was reported at 17.1%, which was higher than the predicted 16.7%. Canaccord's analysis suggests that Merit Medical is on track to achieve its financial objectives outlined in the previous February.
The firm emphasized the company's expressed confidence in its Wrapsody product, noting ongoing plans to submit the final module of its premarket approval (PMA) by the end of the second quarter. This could lead to FDA approval by the end of 2024, assuming standard review timelines.
In light of these developments, Canaccord reaffirmed its Buy rating on Merit Medical's shares. The firm's outlook is buoyed by the potential for continued margin improvement and the anticipated benefits of upcoming new product releases.
InvestingPro Insights
In the wake of Canaccord Genuity's adjusted price target for Merit Medical Systems, Inc. (NASDAQ:MMSI), real-time data from InvestingPro provides additional context for investors considering the stock.
Merit Medical is currently trading at a high earnings multiple, with a P/E ratio of 45.65, which is slightly reduced when adjusted for the last twelve months as of Q4 2023 to 44.07. Despite the high P/E ratio, analysts have revised their earnings upwards for the upcoming period, signaling potential confidence in the company's growth prospects.
The company's revenue growth also remains robust, with a 9.24% increase over the last twelve months as of Q4 2023, and a quarterly increase of 10.6% in Q4 2023. Merit Medical's gross profit margin stands at an impressive 46.44%, illustrating the company's ability to maintain profitability. These metrics underscore the company's solid financial performance and may justify the current market valuation to some investors.
For those looking for more comprehensive analysis, there are 13 additional InvestingPro Tips for Merit Medical available at InvestingPro. To gain in-depth insights and further enhance your investment strategy, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.